Abstract:BackgroundCovalent RNA modifications, such as N-6-methyladenosine (m6A), have been associated with various biological processes, but their role in cancer remains largely unexplored. m6A dynamics depends on specific enzymes whose deregulation may also impact in tumorigenesis. Herein, we assessed the differential abundance of m6A, its writer VIRMA and its reader YTHDF3, in testicular germ cell tumors (TGCTs), looking for clinicopathological correlates.MethodsIn silico analysis of TCGA data disclosed altered expression of VIRMA (52%) and YTHDF3 (48%), prompting subsequent validation. Formalin-fixed paraffin-embedded tissues from 122 TGCTs (2005–2016) were selected. RNA extraction, cDNA synthesis and real-time qPCR (Taqman assays) for VIRMA and YTHDF3 were performed, as well as immunohistochemistry for VIRMA, YTHDF3 and m6A, for staining intensity assessment. Associations between categorical variables were assessed using Chi square and Fisher’s exact test. Distribution of continuous variables between groups was compared using the nonparametric Mann–Whitney and Kruskal–Wallis tests. Biomarker performance was assessed through receiver operating characteristics (ROC) curve construction and a cut-off was established by Youden’s index method. Statistical significance was set at p < 0.05.ResultsIn our cohort, VIRMA and YTHDF3 mRNA expression levels differed among TGCT subtypes, with Seminomas (SEs) depicting higher levels than Non-Seminomatous tumors (NSTs) (p < 0.01 for both). A positive correlation was found between VIRMA and YTHDF3 expression levels. VIRMA discriminated SEs from NSTs with AUC = 0.85 (Sensitivity 77.3%, Specificity 81.1%, PPV 71.6%, NPV 85.3%, Accuracy 79.7%). Immunohistochemistry paralleled transcript findings, as patients with strong m6A immunostaining intensity depicted significantly higher VIRMA mRNA expression levels and stronger VIRMA immunoexpression intensity (p < 0.001 and p < 0.01, respectively).ConclusionAbundance of m6A and expression of VIRMA/YTHDF3 were different among TGCT subtypes, with higher levels in SEs, suggesting a contribution to SE phenotype maintenance. VIRMA and YTHDF3 might cooperate in m6A establishment in TGCTs, and their transcript levels accurately discriminate between SEs and NSTs, constituting novel candidate biomarkers for patient management.

KIAA1429/VIRMA promotes breast cancer progression by m6A‐dependent cytosolic HAS2 stabilization

VIRMA Contributes to Non-Small Cell Lung Cancer Progression Via N6-methyladenosine-dependent DAPK3 Post-Transcriptional Modification.

Effects of RNA Methylation N6-methyladenosine Regulators on Malignant Progression and Prognosis of Melanoma.

Abstract 4827: N6-Methyladenosine Modification of LINC00901 Promotes Pancreatic Cancer Progression

Role of m6A methyltransferase component VIRMA in multiple human cancers (Review)

Overexpression of VIRMA Confers Vulnerability to Breast Cancers Via the M6a-Dependent Regulation of Unfolded Protein Response.

N6-Methyladenosine Methyltransferase Component KIAA1429 Is a Potential Target of Cancer Therapy

Gene amplification‐driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A‐YTHDF2‐dependent in lung adenocarcinoma

KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3

KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner

N6-methyladenosine Modification: an Important Player in the Tumor Immune Microenvironment.

Glycolysis and tumor progression promoted by the m 6 A writer VIRMA via m 6 A-dependent upregulation of STRA6 in pancreatic ductal adenocarcinoma

VIRMA mediates preferential m6A mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenylation

KIAA1429 promotes gastric cancer progression by destabilizing RASD1 mRNA in an m6A-YTHDF2-dependent manner

M6a Methyltransferase KIAA1429 Acts As an Oncogenic Factor in Colorectal Cancer by Regulating SIRT1 in an M6a-Dependent Manner

N6-methyladenosine (m6A) reader IGF2BP2 promotes gastric cancer progression via targeting SIRT1

KIAA1429 promotes the malignancy of oral squamous cell carcinoma by regulating CA9 m6A methylation

Comprehensive Analysis of Expression Regulation for RNA m6A Regulators With Clinical Significance in Human Cancers

m6A RNA modification and its writer/reader VIRMA/YTHDF3 in testicular germ cell tumors: a role in seminoma phenotype maintenance

VIRMA promotes nasopharyngeal carcinoma, tumorigenesis, and metastasis by upregulation of E2F7 in an m6A-dependent manner

VHL governs m6A modification and PIK3R3 mRNA stability in clear cell renal cell carcinomas